RxDoctor Payments Data

Socrates Kakoulides, MD

Cardiovascular Disease · Miami, FLNPI 1437477130

Payments from drug & device makers

$5,621in general payments, 2019–2025

Across 89 payments — averaging $63.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Abbott$811
  • Medtronic$707
  • Lantheus Medical Imaging, Inc.$455
  • Cleerly, Inc.$368
  • Heartflow, Inc.$306
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$5,54199%
  • Education$801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,621 in reported general payments places this provider in the 60th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$166,352
Medicare patients
1,009
Services billed
1,963

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban267$334,349
EntrestoSacubitril/Valsartan134$166,911
FarxigaDapagliflozin Propanediol135$153,839
JardianceEmpagliflozin112$138,226
XareltoRivaroxaban54$62,019
Repatha SureclickEvolocumab33$38,328
OzempicSemaglutide22$20,660
BrilintaTicagrelor11$12,601
Rosuvastatin Calcium506$6,316
Ezetimibe207$5,353
Metoprolol Succinate345$4,986
Atorvastatin Calcium452$4,318
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid27$3,114
Bumetanide93$2,907
Candesartan Cilexetil27$2,326

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$87$334,349267 claims
NovartisEntresto$146$166,911134 claims
AstraZenecaFarxiga, Brilinta$20$166,439146 claims
Johnson & JohnsonXarelto$162$62,01954 claims
Novo NordiskOzempic$37$20,66022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →